Terms: = Pancreatic cancer AND BRCA1, BRCAI, 672, ENSG00000012048, IRIS, BRCC1, RNF53, PSCP AND Treatment
188 results:
1. Olaparib not cost-effective as maintenance therapy for platinum-sensitive, brca1/2 germline-mutated metastatic pancreatic cancer.
Mehra T; Lupatsch JE; Kössler T; Dedes K; Siebenhüner AR; von Moos R; Wicki A; Schwenkglenks ME
PLoS One; 2024; 19(4):e0301271. PubMed ID: 38573891
[TBL] [Abstract] [Full Text] [Related]
2. Population-based BRCA germline mutation screening in the Han Chinese identifies individuals at risk of BRCA mutation-related cancer: experience from a clinical diagnostic center from greater Shanghai area.
Wu Z; Zhang Q; Jin Y; Zhang X; Chen Y; Yang C; Tang X; Jiang H; Wang X; Zhou X; Yu F; Wang B; Guan M
BMC Cancer; 2024 Apr; 24(1):411. PubMed ID: 38566028
[TBL] [Abstract] [Full Text] [Related]
3. pancreatic cancer biomarkers: A pathway to advance in personalized treatment selection.
Brozos-Vázquez E; Toledano-Fonseca M; Costa-Fraga N; García-Ortiz MV; Díaz-Lagares Á; Rodríguez-Ariza A; Aranda E; López-López R
Cancer Treat Rev; 2024 Apr; 125():102719. PubMed ID: 38490088
[TBL] [Abstract] [Full Text] [Related]
4. Abrogation of KLF5 sensitizes
Zhang Z; Liu Y; Xu Y; Xu Z; Jia J; Jin Y; Wang W; Liu L
Acta Biochim Biophys Sin (Shanghai); 2024 Apr; 56(4):576-585. PubMed ID: 38433576
[TBL] [Abstract] [Full Text] [Related]
5. A Somatic BRCA2-Mutated pancreatic Adenocarcinoma With Sustained Exceptional Response to Modified FOLFIRINOX.
Jamison JK; May MS; Raufi AG; Luk L; Wong W; Mundi PS; Manji GA
Oncologist; 2024 Apr; 29(4):350-355. PubMed ID: 38394390
[TBL] [Abstract] [Full Text] [Related]
6. Germline mutations of homologous recombination genes and clinical outcomes in pancreatic cancer: a multicenter study in Taiwan.
Cheng SM; Su YY; Chiang NJ; Wang CJ; Chao YJ; Huang CJ; Tsai HJ; Chen SH; Chang CY; Tsai CR; Li YJ; Yen CJ; Chuang SC; Chang JS; Shan YS; Hwang DY; Chen LT
J Biomed Sci; 2024 Feb; 31(1):21. PubMed ID: 38350919
[TBL] [Abstract] [Full Text] [Related]
7. Targeting BRCA and PALB2 in pancreatic cancer.
Anbil S; Reiss KA
Curr Treat Options Oncol; 2024 Mar; 25(3):346-363. PubMed ID: 38311708
[TBL] [Abstract] [Full Text] [Related]
8. A novel targeted NGS panel identifies numerous homologous recombination deficiency (HRD)-associated gene mutations in addition to known BRCA mutations.
Vogel A; Haupts A; Kloth M; Roth W; Hartmann N
Diagn Pathol; 2024 Jan; 19(1):9. PubMed ID: 38184614
[TBL] [Abstract] [Full Text] [Related]
9. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment.
Ikezawa K; Urabe M; Kai Y; Takada R; Akita H; Nagata S; Ohkawa K
Jpn J Clin Oncol; 2024 Mar; 54(3):271-281. PubMed ID: 38109477
[TBL] [Abstract] [Full Text] [Related]
10. SAKK57/16 Nab-paclitaxel and Gemcitabine in Soft Tissue Sarcoma (NAPAGE): a phase I/II trial.
Digklia A; Kollár A; Dietrich D; Kronig MN; Britschgi C; Rordorf T; Joerger M; Krasniqi F; Metaxas Y; Colombo I; Ribi K; Rothermundt C
Eur J Cancer; 2024 Jan; 197():113470. PubMed ID: 38096656
[TBL] [Abstract] [Full Text] [Related]
11. Cost-Effectiveness Analysis of Screening for pancreatic cancer Among High-Risk Populations.
Peters MLB; Eckel A; Seguin CL; Davidi B; Howard DH; Knudsen AB; Pandharipande PV
JCO Oncol Pract; 2024 Feb; 20(2):278-290. PubMed ID: 38086003
[TBL] [Abstract] [Full Text] [Related]
12. brca1/2 reversion mutations in a pan-cancer cohort.
Nakamura K; Hayashi H; Kawano R; Ishikawa M; Aimono E; Mizuno T; Kuroda H; Kojima Y; Niikura N; Kawanishi A; Takeshita K; Suzuki S; Ueno S; Okuwaki K; Sasaki J; Yamaguchi M; Masuda K; Chiyoda T; Yamagami W; Okada C; Nohara S; Tanishima S; Nishihara H
Cancer Sci; 2024 Feb; 115(2):635-647. PubMed ID: 38041241
[TBL] [Abstract] [Full Text] [Related]
13. DAXX promotes centromeric stability independently of ATRX by preventing the accumulation of R-loop-induced DNA double-stranded breaks.
Pinto LM; Pailas A; Bondarchenko M; Sharma AB; Neumann K; Rizzo AJ; Jeanty C; Nicot N; Racca C; Graham MK; Naughton C; Liu Y; Chen CL; Meakin PJ; Gilbert N; Britton S; Meeker AK; Heaphy CM; Larminat F; Van Dyck E
Nucleic Acids Res; 2024 Feb; 52(3):1136-1155. PubMed ID: 38038252
[TBL] [Abstract] [Full Text] [Related]
14. PARP Inhibitor Sensitizes
Kim C; Kim D; Lee DS; Lee S; Yoo C; Kim KP
Anticancer Res; 2023 Dec; 43(12):5523-5534. PubMed ID: 38030179
[TBL] [Abstract] [Full Text] [Related]
15. High intramuscular adipose tissue content associated with prognosis and postoperative complications of cancers.
Liu R; Qiu Z; Zhang L; Ma W; Zi L; Wang K; Kuang T; Zhao K; Wang W
J Cachexia Sarcopenia Muscle; 2023 Dec; 14(6):2509-2519. PubMed ID: 37990969
[TBL] [Abstract] [Full Text] [Related]
16. Strategies for the Management of Patients with pancreatic cancer with PARP Inhibitors.
Golan T; Raitses-Gurevich M; Beller T; Carroll J; Brody JR
Cancer Treat Res; 2023; 186():125-142. PubMed ID: 37978134
[TBL] [Abstract] [Full Text] [Related]
17. Clinical features of germline brca1/2 or ATM pathogenic variant positive pancreatic cancer in Japan.
Kitamura H; Morizane C; Tanabe N; Go I; Maruki Y; Ohba A; Nagashio Y; Kondo S; Hijioka S; Ueno H; Yoshida T; Okusaka T
Pancreatology; 2023 Dec; 23(8):964-969. PubMed ID: 37914629
[TBL] [Abstract] [Full Text] [Related]
18. CRISPR/Cas9-mediated knock-in of brca1/2 mutations restores response to olaparib in pancreatic cancer cell lines.
Witz A; Dardare J; Francois A; Husson M; Rouyer M; Demange J; Merlin JL; Gilson P; Harlé A
Sci Rep; 2023 Oct; 13(1):18741. PubMed ID: 37907567
[TBL] [Abstract] [Full Text] [Related]
19. Efficacy of olaparib in advanced cancers with germline or somatic mutations in brca1, BRCA2, CHEK2 and ATM, a Belgian Precision tumor-agnostic phase II study.
Joris S; Denys H; Collignon J; Rasschaert M; T'Kint de Roodenbeke D; Duhoux FP; Canon JL; Tejpar S; Mebis J; Decoster L; Aftimos P; De Grève J
ESMO Open; 2023 Dec; 8(6):102041. PubMed ID: 37852034
[TBL] [Abstract] [Full Text] [Related]
20. Clinical characterization of patients with gbrca1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.
Kubo T; Muramatsu J; Arihara Y; Murota A; Ishikawa K; Yoshida M; Nagashima H; Tamura F; Ikeda Y; Usami M; Ono M; Nakamura H; Watanabe D; Shibata T; Kasahara K; Sakurai A; Takada K
Jpn J Clin Oncol; 2024 Jan; 54(1):47-53. PubMed ID: 37791389
[TBL] [Abstract] [Full Text] [Related]
[Next]
